IBM nanomedicine breakthrough to aid antibiotics

Summary:IBM researchers and scientists from the Institute of Bioengineering and Nanotechnology have unveiled biodegradable nanoparticles that could help fend off drug-resistant infections

IBM researchers and scientists from the Institute of Bioengineering and Nanotechnology on Sunday unveiled a nanomedicine breakthrough — biodegradable nanoparticles that make antibiotics physically attracted to infected cells.

This nanomedicine application could represent a new drug delivery method to fend off drug-resistant infections such as Methicillin-resistant Staphylococcus (MRSA) and other bacteria. James Hedrick, lead scientist for the project at IBM, said the findings could lead to a wide variety of uses from healing wounds to emergency uses in a war.

While the breakthrough holds promise in delivering medicine such as antibiotics one of the more striking things is how semiconductor manufacturing applies to producing organic material. For instance, chips require small wiring and cramming together ever-shrinking transistors in a precise way. Organic nanostructures require the same.

For more on this ZDNet UK-selected story, see IBM: Applying semiconductor knowhow to organic nanostructures on ZDNet.com.


Get the latest technology news and analysis, blogs and reviews delivered directly to your inbox with ZDNet UK's newsletters.

Topics: Emerging Tech

About

Larry Dignan is Editor in Chief of ZDNet and SmartPlanet as well as Editorial Director of ZDNet's sister site TechRepublic. He was most recently Executive Editor of News and Blogs at ZDNet. Prior to that he was executive news editor at eWeek and news editor at Baseline. He also served as the East Coast news editor and finance editor at CN... Full Bio

zdnet_core.socialButton.googleLabel Contact Disclosure

Kick off your day with ZDNet's daily email newsletter. It's the freshest tech news and opinion, served hot. Get it.

Related Stories

The best of ZDNet, delivered

You have been successfully signed up. To sign up for more newsletters or to manage your account, visit the Newsletter Subscription Center.
Subscription failed.